Loss of CDKN2A was also commonly found in BRAFi resistant melanomas and is linked to the MAPK pathway as an inhibitor of the downstream effectors cyclin D and cyclin-dependent kinase 4 (CDK4) [59,64]. This evidence concerns the gene CDKN2A and melanoma.